Side-by-side comparison of AI visibility scores, market position, and capabilities
AI biology lab building protein design models (ESM3, 98B params). Founded 2023 by ex-Meta scientists. $142M seed. Acquired by Chan Zuckerberg Biohub Nov 2025.
EvolutionaryScale was an AI research lab founded in 2023 by former Meta AI protein team scientists, including CEO Alexander Rives. Based in New York City, the company developed frontier AI models for protein design and biological discovery. Its flagship model ESM3 is a 98-billion-parameter generative AI system trained on 2.78 billion protein sequences capable of reasoning over protein sequence, structure, and function simultaneously.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
EvolutionaryScale vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.